EGFR and non-small cell lung carcinoma: 69,70 Monitoring the clearance of EGFR-clones in ctDNA has been described as a response predictor for EGFR tyrosine kinase inhibitors.23,71,72 Pooled results from our analysis revealed that patients with NSCLC who exhibited clearance of EGFR mutant clones in ctDNA demonstrated benefits in PFS (HR: 0.30 [0.22, 0.41], 95% CI) and OS (HR: 0.31 [0.19, 0.50], 95% CI).